Ovarian Cancer

Early Detection Of Ovarian Cancer Is Critical

Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths among women. Ovarian cancer is often diagnosed too late as four out of five ovarian cancer patients are diagnosed with advanced disease. Early intervention can significantly improve survival rates and is crucial for women who are known to be at higher risk for the disease. ClearNote Health has developed the Avantect Ovarian Cancer Test for women with high risk for ovarian cancer who carry genetic predispositions such as BRCA1, BRCA2 mutations or have a first-degree family member with ovarian cancer.

Explore The Avantect Ovarian Cancer Test

Sources:
American Cancer Society 2022
SEER12 – https://seer.cancer.gov/statfacts/html/ovary.html (accessed April 14, 2023)
Stage Distribution of SEER Incidence Cases, 2010-2019​
Data on file

Tracking Epigenomic Signals To Detect Cancer Early

Learn About Our Platform
ClearNote Health
Privacy Overview

We use cookies, subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie policy for more information.
Read our privacy policy to understand how ClearNote Health handles personal information that we collect through our digital properties that link to this Privacy Policy, including our website and other activities described in the privacy policy.